📈RESEARCH NOTES : CRESO PHARMA (CPH)
TARGET BUY IN: 0.60 - 0.70💰
CPH has a very diverse profile: ✅ Animal Health - Treatments for targeting animal stress and pain relief. IMO, CPH may have a better chance than CP1 and other MM companies to break into this market. ✅ Therapeutic: CPH is progressing in the medical cannabis industry ✅ Nutraceuticals: CPH has products such as cannaQIX. ✅ Skin care: CPH is trying to produce products that will improve skin health and appearance.
TIMELINE: 📌 One of the main reasons i have invested is because CPH is the first in Australia to import cannabis oils from Canada for early access patients. This will be done through the CannaQix product line. This product line is due to launch in Q4 of 2018. 📌 Revenues have increased dramatically, jumping from $8,022 in 2016 to $243,798 in 2017. Now these figures are no where near impressive, but its good to see them increasing their revenue. These companies need to start somewhere. 📌 In 2018, CPH reported their first revenue of $311,940 from cannaQix which includes sales of CPH’s animal health product. 📌 Who doesn’t love bit of weed beer and chocolates. CPH has branded chocolates and beverages. 📌 Skincare products are going to be launched at the start of 2019. 📌Mernova deal: Cresto has commenced construction of the planting site. MAY 2018 expected for construction to be completed. JUN 2018 first crop planted. AUGUST, Health Canada will inspect the site and SEPTEMBER 2018 the first crop will be harvested. This will become online and start delivering revenues in Canada. 📌 Introduction of cannaQix50 to Australia and New Zealand in Q3 2018. 📌 Expand anibidol (animal health) to other countries 📌 First revenues from Kunna Q4 2018.
IMO i see CPH sitting well above $1 in the next couple of months. I have said this before, revenue is key. I am happy to top up next few days. There is a lot due in the coming weeks.